SERDs and Novel ET in ER+/HER2- Breast Cancer
Oral SERDs and Novel Endocrine Therapies: Reshaping the Treatment Landscape for ER+/HER2- Breast Cancer

Released: December 01, 2023

Erika P. Hamilton
Erika P. Hamilton, MD
Kevin Kalinsky
Kevin Kalinsky, MD, MS

Activity

Progress
1
Course Completed